References
- https://www.who.int/news-room/q-a-detail/ultraviolet-(uv)-radiation-and-skin-cancer. Accessed on Aug 3, 2020.
- https://www.cancer.org/cancer/melanoma-skin-cancer/about/key-statistics.html. Accessed on Aug. 3rd, 2020.
- Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418:934.
- Abdel-Maksoud M, El-Gamal M, Gamal El-Din M, et al. Design, synthesis, in vitro anticancer evaluation, kinase inhibitory effects, and pharmacokinetic profile of new 1,3,4-triarylpyrazole derivatives possessing terminal sulfonamide moiety. J Enzyme Inhib Med Chem 2019;34:97–109.
- Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010;467:596–9.
- Honndorf VS, Coudevylle N, Laufer S, et al. Dynamics in the p38alpha MAP kinase-SB203580 complex observed by liquid-state NMR spectroscopy. Angew Chem Int Ed Engl 2008;47:3548–51.
- Rheault TR, Stellwagen JC, Adjabeng GM, et al. Discovery of Dabrafenib: a selective inhibitor of Raf kinases with antitumor activity against B-Raf-driven tumors. ACS Med Chem Lett 2013;4:358–62.
- Karoulia Z, Gavathiotis E, Poulikakos PI. New perspectives for targeting RAF kinase in human cancer. Nat. Rev. Cancer 2017;17:676–91.
- Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099–109.
- Lapierre J-M, Namdev ND, Ashwell MA, et al. RAF inhibitors and their uses. PCT Pat Appl WO 2007/123892.
- Abdel-Maksoud MS, Kim M-R, El-Gamal MI, et al. Design, synthesis, in vitro antiproliferative evaluation, and kinase inhibitory effects of a new series of imidazo[2,1-b]thiazole derivatives. Eur J Med Chem 2015;95:453–63.
- Ammar UM, Abdel-Maksoud MS, Ali EMH, et al. Structural optimization of imidazothiazole derivatives affords a new promising series as B-Raf V600E inhibitors; synthesis, in vitro assay and in silico screening. Bioorg Chem 2020;100:103967
- Park J-H, Oh C-H. Synthesis of new 6-(4-fluorophenyl)-5-(2-substituted pyrimidin-4-yl)imidazo[2,1-b]thiazole derivatives and their antiproliferative activity against melanoma cell line. Bull Korean Chem Soc 2010;31:2854–60.
- Park J-H, El-Gamal MI, Lee YS, et al. New imidazo[2,1-b]thiazole derivatives: Synthesis, in vitro anticancer evaluation, and in silico studies. Eur J Med Chem 2011;46:5769–77.
- Abdel-Maksoud MS, El-Gamal MI, Gamal El-Din MM, et al. Broad-spectrum antiproliferative activity of a series of 6-(4-fluorophenyl)-5-(2-substituted pyrimidin-4-yl)imidazo[2,1-b]thiazole derivatives. Med Chem Res 2016;25:824–33.
- El-Gamal MI, Abdel-Maksoud MS, Gamal El-Din MM, et al. Synthesis, in vitro antiproliferative and antiinflammatory activities, and kinase inhibitory effects of new 1,3,4-triarylpyrazole derivatives. Anticancer Agents Med Chem 2017;17:75–84.
- Pedretti A, Villa L, Vistoli G. Atom-type description language: a universal language to recognize atom types implemented in the VEGA program. Theor Chem Acc 2003;109:229–32.
- Pedretti A, Villa L, Vistoli G. VEGA – An open platform to develop chemo-bio-informatics applications, using plug-in architecture and script programming. J Comput Aid Mol Des 2004;18:167–73.
- Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010;31:455–61.
- Baroni M, Cruciani G, Sciabola S, et al. A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for Ligands and Proteins (FLAP): theory and application. J Chem Inf Model 2007;47:279–94.
- Cross S, Baroni M, Goracci L, et al. GRID-Based Three-Dimensional Pharmacophores I: FLAPpharm, a Novel Approach for Pharmacophore Elucidation. J Chem Inf Model 2012;52:2587–98.
- Milletti F, Storchi L, Sforna G, et al. New and original pKa prediction method using grid molecular interaction fields. J Chem Inf Model 2007;47:2172–81.
- Crivori P, Cruciani G, Carrupt P-A, et al. Predicting blood-brain barrier permeation from three-dimensional molecular structure. J Med Chem 2000;43:2204–16.
- Cruciani G, Crivori P, Carrupt P-A, et al. Molecular fields in quantitative structure-permeation relationships: the VolSurf approach. Theochem 2000;503:17–30.
- Gramatica P, Chirico N, Papa N, et al. QSARINS: a new software for the development, analysis, and validation of QSAR MLR models. J Comput Chem 2013;34:2121–32.
- Gramatica P, Cassani S, Chirico N. QSARINS-chem: Insubria datasets and new QSAR/QSPR models for environmental pollutants in QSARINS. J Comput Chem 2014;35:1036–44.
- Ashwell M, Tandon M, Lapierre J-M. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase. PCT Patent Application WO 2006044869, 2006.
- Tully DC, Liu H, Chatterjee AK, et al. Synthesis and SAR of arylaminoethyl amides as noncovalent inhibitors of cathepsin S: P3 cyclic ethers. Bioorg Med Chem Lett 2006;16:5112–7.
- Townsend CA, Basak A. Experiments and speculations on the role of oxidative cyclization chemistry in natural product biosynthesis. Tetrahedron 1991;47:2591–602.
- Sumimoto H, Imabayashi F, Iwata T, et al. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 2006;203:1651–6.
- Carosati E, Sciabola S, Cruciani G. Hydrogen bonding interactions of covalently bonded fluorine atoms: From crystallographic data to a new angular function in the GRID force field. J Med Chem 2004;47:5114–25.